| Literature DB >> 32351160 |
Samu Hemmilä1, Marika Ruponen2, Elisa Toropainen2, Unni Tengvall-Unadike2, Arto Urtti2,3,4, Pasi Kallio1.
Abstract
This paper presents a novel microflow-based concept for studying the permeability of in vitro cell models or ex vivo tissues. Using the proposed concept, we demonstrate how to maintain physiologically relevant test conditions and produce highly reproducible permeability values for a range (31) of drug compounds. The apparent permeability coefficients (Papp) showed excellent correlation (0.89) with the values from experiments performed with a conventional Ussing chamber. Additionally, the microflow-based concept produces notably more concentrated samples than the conventional Ussing chamber-based approach, despite the fact that more than 10 times smaller quantities of test compounds and biological membranes are needed in the microflow-based concept.Entities:
Keywords: ex vivo; in vitro; microfluidics; permeability
Mesh:
Substances:
Year: 2020 PMID: 32351160 PMCID: PMC7509603 DOI: 10.1177/2472630320916190
Source DB: PubMed Journal: SLAS Technol ISSN: 2472-6303 Impact factor: 3.047
Figure 1.The device developed for in vitro and ex vivo permeability studies includes (a) a control unit, and disposable plastic components called (b) a membrane holder, (c) a flow component, and (d) a donor component. The specific environment used in an experiment is generated inside an experiment chamber of the control unit, where the disposables are in contact with the studied molecules and membranes.
Figure 2.Schematic presentation of one of the six parallel permeability experiments inside the experiment chamber, in a controlled and stable environment. The membrane being studied is placed into the membrane holder, on top of which is the donor component containing a donor medium. The donor medium includes the drug molecules under study. The molecules penetrate the membrane and enter a recipient medium, after which the flowing recipient medium transports the molecules through the flow channel to the sample liquid outlet, from where the sample is collected and analyzed.
Drug Molecules in the Cassette Mix.[25]
| Acetazolamide | Betaxol | Diclofenac | Levocobastine | Pilocarpine |
| Acyclovir | Brinzolamide | Dorzolamide | Lincomycin | Pindolol |
| Ampicillin | Bromfenac | Fluconazole | Lornoxicam | Prednisolone |
| Atropine | Carteolol | Ganciclovir | Methazolamide | Propranolol |
| Atenolol | Ciprofloxacin | Indomethacin | Methotrexate | Quinidine |
| Aztreonam | Dexamethasone | Ketorolac | Nadolol | Tizanidine |
| Voriconazole |
Summary of the Control Unit Validation.
| Temperature (°C) | Flowrate (µL/min) | pH | |
|---|---|---|---|
| Target value | 37.0 | 1.0 | 7.46 |
| Measured (average ± SD) | 36.6 ± 0.4 | 1.1 ± 0.1 | 7.45 ± 0.02 |
Figure 3.The mean drug concentration in the receiver side as a function of time (a) in the microflow-based device and (b) in the Ussing chamber. The number of parallel tissues was 5–11 and 3 in the studies with the microflow device and the Ussing chamber, respectively.
Figure 4.Apparent permeability coefficient (Papp) values for porcine cornea obtained with the microflow-based device (n = 5–11 ± SD) and the Ussing chamber (n = 2–7 ± SD; Ramsay et al.[26]).
Figure 5.Correlation between the Papp values obtained by the microflow-based device and the Ussing chamber. The values with the microflow-based device are on average 1.65 ± 0.45 times higher than the ones obtained with the Ussing chamber. This is illustrated in the figure by the black trend lines.